According to Hayward et al’s study, the most prominent mutation—identified in 56% of tumors—is represented by the hemi- or homozygous deletion of CDKN2A, while its alteration by methylation was detected in a reduced proportion of cases.[2] In our evaluation, CDKN2A homozygous deletion and monosomy were present in the majority of cases, totaling 60.86% of the analyzed melanoma specimens from patients with MPM and/or familial cutaneous melanoma. The gene discussed is CDKN2A; the disease is melanoma.